Overview

Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)

Status:
Terminated

Trial end date:
2015-01-26

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the efficacy of a short course of therapy (24 weeks) versus standard 48 week treatment in previously untreated adult participants with chronic hepatitis C (CHC) genotype 4 infection who achieve rapid virologic response (RVR), defined as HCV ribonucleic acid (RNA) negativity after 4 weeks of treatment.

Phase:

Phase 4

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Interferon alpha-2
Interferon-alpha
Peginterferon alfa-2b
Ribavirin